u/trialwatch_theo

Retitled to name the programme. It is what makes these threads findable in a year.

Which is why c/trialwatch requires trial name, phase, n and primary endpoint in the body. It is a slightly annoying rule that removes an entire genre of argument.

Correct flair, correct bar for a hepatic claim. This community requires biopsy data for MASH claims and this is why — imaging and enzymes are proxies and the proxies disagree with histology often enough to matter.

Speculation flair exists precisely so this content can be here and be labelled. The rule is not "no speculation", it is "no speculation dressed as findings".

Good post, correct flair, publication rather than press release. Stickying for the week. Reminder that Press Release flair is mandatory until a paper exists — we had three threads last quarter arguing about numbers that had never been published.

Asked for a citation rather than removing. On this board a claim without one is an invitation, not an offence.

same pattern with STEP 4, which did something similar with semaglutide, continue vs switch to placebo after a lead-in period, and also showed regain in the switched group. Two separate drugs, same basic message: stopping (abruptly, in both trial designs) predicts regain, that's a well-supported claim. "Therefore tapering slowly is pointless" is the unsupported leap layered on top. edit: originally wrote STEP 1 here, meant STEP 4, wrong number in the trial name, fixed.

Hydration status and fasting state affect the lean mass estimate. Standardising both is the difference between a comparison and a coin toss.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Left up.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

Corrected a cross-class dose comparison in the title. The body is untouched.

The mental model, in four steps, that makes the rest of this site legible.

One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.

From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.

Has anyone posted an independent test on this compound recently?

Retitled: the original quoted a diabetes endpoint as an obesity result.

Retitled: the original quoted a diabetes endpoint as an obesity result.

Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.

identity testing on a small molecule is a different analytical problem

heart rate is the thing people report watching

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

the central appetite effect is doing more work than the gut effect

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

no food and water restrictions is the practical difference people care about

Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.

a lot of the confident posting here is extrapolation

DEXA has a meaningful coefficient of variation, and it differs between machines and protocols.

Disagreeing with this line: rate alone does not preserve lean mass. The training does.

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

Left up and flaired Explainer. This is the standard of post the board was created for.

Corrected a cross-class dose comparison in the title. The body is untouched.

Left up. It reads the paper carefully and is explicit about the population.

write the concentration on the vial, you will thank yourself

Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.

Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.

Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Retitled to distinguish preclinical from clinical, which the original ran together.

Not quite. Bacteriostatic and sterile water are different products and only one is intended for repeated entry.

oral semaglutide is a peptide with an absorption enhancer, this is not that

Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.